FDA 483 OBSERVATION · #69 OF 1,923 MOST-CITED
Control procedures to monitor and validate performance
FDA cited this observation 357 times across 328 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The drug manufacturer did not establish or follow adequate control procedures to monitor the output and validate the performance of the manufacturing processes that may cause variability in the characteristics of in-process material and the finished product.
Why FDA writes it — In-process controls are how you catch variability while a batch can still be corrected. Without them, a process can drift out of control and the problem is only discovered — if at all — at final testing, after the whole batch is affected.
- Establish written procedures to monitor the output and validate the performance of processes that may cause variability in in-process and finished-product characteristics.
- Define in-process specifications and sampling/testing (e.g., tablet weight, hardness, pH, dissolution as applicable) with valid statistical or scientific bases.
- Take in-process samples and test at appropriate points, and act when results are out of limits.
- Reject or investigate in-process material that fails to meet specifications.
- No in-process monitoring, so process drift is only found at final release.
- In-process limits set without a valid statistical or scientific basis.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 4.8× the rate of the average FDA-cited firm (37.2% vs 7.8%), across 328 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →